PATENT CLAIM ANALYSIS

Application Number: 15878877
Application Type: Utility
Filing Date: 2018-01
Publication Date: 2018-07
Patent Classification: ["564", "381000"]

Abstract:
The present invention relates to a process for the preparation of selegiline base, an irreversible and selective inhibitor of the MAO-B enzymes and which is used in the treatment of Parkinson's Disease.

Claim (Index 1):
A process for the preparation of selegiline base of formula (I): comprising:\n the reaction of the hydrochloride addition salt of selegiline of formula (II) \n \u2003with a base in an aqueous solution forming a biphasic mixture; the separation of selegiline base of formula (I) from the aqueous solution; the anhydrification by drying selegiline base of formula (I) or by freezing selegiline base of formula (I) at a temperature below 0\u00b0 C., and wherein the ratio of the hydrochloride addition salt of selegiline of formula (II) and the aqueous content during the reaction of the hydrochloride addition salt with the base is equal or superior to 100 mg/1 mL water.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 86.0
- Lexical Diversity: 1.16667
- Patent Class: 564.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14773397', '12602348', '13263397', '12858779', '16066402']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6963025874136437
- 35 USC 102 Novelty (BERT): 0.4994272584740549
- Combined Prediction Score: 0.6766150545196848
- Mean Citation Score: 177.256078
- Max Citation Score: 185.17592
- Similarity Product: 135.71257743996142

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test